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ABSTR ACT: The immune system is perhaps the largest yet most diffuse and distributed somatic system in vertebrates. It plays vital roles in fighting infec-
tion and in the homeostatic control of chronic disease. As such, the immune system in both pathological and healthy states is a prime target for therapeutic 
interventions by drugs—both small-molecule and biologic. Comprising both the innate and adaptive immune systems, human immunity is awash with 
potential unexploited molecular targets. Key examples include the pattern recognition receptors of the innate immune system and the major histocompat-
ibility complex of the adaptive immune system. Moreover, the immune system is also the source of many current and, hopefully, future drugs, of which 
the prime example is the monoclonal antibody, the most exciting and profitable type of present-day drug moiety. This brief review explores the identity 
and synergies of the hierarchy of drug targets represented by the human immune system, with particular emphasis on the emerging paradigm of systems 
pharmacology.
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Compared with, say, the nervous system, a system of simi-
lar complexity and importance, the immune ystem is a more 
diffuse, less discreet entity comprised of molecules and cells, 
as well as macroscopic organs. It is less centralized and less 
localized but is prone to the same cooperative, emergent 
behavior common to all systems comprising elements operat-
ing at different time and length scales. The immune system 
is both a bulwark against infection and a crucial homeostatic 
mechanism; thus, it protects the viability while maintaining 
the integrity of the host organism. Part of the de facto protec-
tive role of human immunity is to control and suppress chronic 
disease states and pathologies, as well as protect against the 
pernicious effects of infectious organisms. Despite, and yet 
because of, the immune system’s protective role, it is also an 
expanding target for therapeutic and prophylactic drugs.
Illness has many sources, including life-threatening con-
ditions arising from infectious, genetic, or autoimmune dis-
ease, as well as conditions impinging deleteriously on quality 
of life. Yet, there is seldom a clear distinction between dis-
ease causes. Genetic disease can result from Mendelian or 
from multifactorial inheritance. In Mendelian conditions—
such as cystic fibrosis, thalassemia, Tay-Sachs disease, or 
 tyrosinemia—an altered phenotype arises from mutations to 
a single dominant gene or to 2 recessive genes. In multifacto-
rial inheritance—such as asthma, heart disease, and type II 
diabetes—mutations in many distinct genes, combined with 
a significant environmental contribution, give rise to disease. 
Identifying genes leading to Mendelian disorders has often 
proved outstandingly successful. By contrast, multifactorial 
diseases seldom yield clear-cut causative genes. Genome-wide 
association studies (GWAS) have begun to open a flood-gate 
of such susceptibility genes for multifactorial diseases,1 but 
with knowledge has not come simplicity or understanding. 
The nature of inheritance in multifactorial diseases is probably 
so complicated that the interaction of genes, modifier genes, 
and causative multiple mutations (necessary for a changed 
phenotype to be seen) may continue to defy straightforward 
identification. Disease also arises as the homeostatic mecha-
nisms of the immune system are subverted or fail, leading to 
autoimmunity and inappropriate immune reactions.
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The immune system is thus a key target for drug inter-
vention both when the system works and when the system 
fails; augmenting the functional immune system aids the fight 
against both chronic and infectious disease, while stymieing 
inappropriate immune responses can mitigate autoimmu-
nity and the potentially catastrophic effects of the misfiring 
immune system. The immunity comprises the innate and the 
adaptive immune systems, both targets and potential sources 
of drug moieties.
While it is always possible to subdivide any complex topic 
in many relevant and interesting ways, it is fairly clear that 
this topic falls quite neatly into the following tripartite struc-
ture. First are pharmaceutical products that induce immune 
responses, immunization against pathogens, and tumors. 
These his would include, inter alia, adjuvants, DNA vaccines, 
and dendritic cell vaccines. Second are drugs that modulate 
immune responses against self-reactive autoimmune diseases. 
Such drugs might target mechanisms as diverse as tolerance 
induction, Th1/Th2 shift, anti-cytokine treatments, and non-
specific immune suppression. Third are drugs that stimulate 
the immune system to target nonimmunological diseases, 
which include prophylactic immunization against Alzheimer’s, 
Parkinson’s, and other chronic or degenerative disease states.
The immune system is both a target itself and a hierar-
chy of individual, identifiable targets of increasing size and 
complexity. As an emergent system, the immune system can 
be seen as something greater than the sum of its parts and 
capable of distinct, autonomous behavior at many levels. It can 
respond and be targeted in many ways, at many length scales, 
and on various time scales. Thus, a pathogen may attack 
the body by secreting individual small molecules such as 
 siderophores,2 by secreting proteins such as toxins, or by using 
supramolecular complexes such as type-IV secretion systems 
to puncture holes into the cytoplasm of eukaryotic cells. 
A pathogen may also attack the body by being engulfed as a 
whole cell by a whole cell, as is the case with TB bacteria,3 or 
cooperatively, through quorum sensing, to attack larger scale 
structures. Likewise, the immune and associated systems pro-
duce small antimicrobial peptides. These systems also produce 
proteins, such as neutrophil gelatinase-associated lipocalin, to 
bind siderophores, and these systems also recognize bacterial 
components, triggering large-scale, highly-diverse immune 
responses, and so on.
For the last few decades, which follow a largely empiri-
cal, targetless prehistory, drug discovery has mainly, if not 
exclusively, concentrated on membrane-bound receptor pro-
teins and enzymes as principal targets. This has led to a one- 
receptor-one-disease-one-drug paradigm that presupposes 
highly selective drugs. Although this view is now in flux, it 
remains compelling. Drugs take many forms, but the domi-
nant triad comprise small molecules, protein biologics, and 
vaccines. Small molecule drugs may be wholly synthetic, 
such as cimetidine; natural products, such as taxol; or syn-
thetic analogues of a natural product. After decades of futile 
 high-throughput screening, drug design has returned to the 
natural product.4 Analyses of natural products have found that 
they differ in several key properties from commercially avail-
able compound libraries. Natural products typically incorpo-
rate fewer nitrogens, aromatic rings, and rotatable bonds per 
compound than synthetic drugs yet contain more oxygens, 
more chiral centres, and more fused rings. This suggests natu-
ral products are characterized by rigid, nonflat, intrinsically 
three-dimensional structures. This may increase the chance of 
clinical success for candidate drugs, since compound unsatu-
ration and chirality increases as drugs develop.5
Peptides are also regaining ground as potential therapeu-
tic agents. Like small molecules, they can be designed using 
paradigms from rational drug design. Leveraging the power 
of computational chemistry in all its guises, we can within 
the immune context design novel, nonnatural sequences that 
might act as heteroclitic peptides, superagonists, antagonists, 
or blockers of MHC mediated T-cell responses.  Doytchinova 
et al used a model of A2 binding to design superbinders with 
affinities up to 2.5 orders of magnitude greater than the most 
affine natural peptide sequences.6 They were also able to 
alter systematically the amino acid identity of anchor posi-
tions showing that peptides with at least 10 residues other 
than canonical anchors can be bound at or above the affin-
ity threshold concomitant with putative immunogenicity. 
The same design principles can be applied to any physical 
or biological property of peptides, allowing us to tailor their 
pharmacokinetics and immunogenic qualities in much the 
same way medicinal chemists have optimized small molecules 
for decades.
The immune system is replete with receptors, enzymes, 
and targetable receptors of all types. A particularly interest-
ing, even exciting, example of protein target is provided by the 
so-called pattern recognition receptors (or PRRs) that medi-
ate the recognition of pathogen-associated molecular pattern 
(or PAMP) by the innate immune system.7 As we shall see, 
they are potential targets for small molecule adjuvants.8
Adjuvants potentiate immune responses, reducing the 
dosing requirements needed to induce protective immunity, 
particularly for weakly immunogenic subunit vaccines. Few 
adjuvants are licensed for human use. These comprise prin-
cipally alum and squalene-based oil-in-water adjuvants. Yet 
there are many types of potential adjuvant, including proteins, 
oligonucleotides, drug-like small molecules, and liposome-
based delivery systems. So-called small molecule adjuvants 
(SMAs) are the most underexplored extant adjuvants, even 
though many small molecules exhibit adjuvant properties. 
Extant SMAs include both complex biologically derived nat-
ural products and fully synthetic drug-like molecules.9 Nota-
ble natural product SMAs include QS21; muramyl dipeptide; 
mannide monooleate, typically formulated as an oil-in-water 
adjuvant such as montanide ISA 720 and montanide ISA 51; 
MurNAc-L-Ala-γ-D-Glu-mDAP (M-TriDAP); and mono-
phosphoryl lipid A (or MPL).
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Fully synthetic drug-like small molecules are also 
adjuvants,9 for example, bestatin (ubenimex or UBX), levami-
sole, bupivacaine, and 2-(4-methoxyphenyl)-N-methyletha-
namine (also known as compound 48/80). Yet easily the best 
explored of SMAs are the so-called imidazoquinolines, the 
best known of which are imiquimod, resiquimod, and gardiqui-
mod. These target Toll-like receptors, that is, TLR7 and/or 
TLR8, inducing IFN, TNF, and IL-12 secretion. SMAs can 
also be discovered in a rational and systematic manner.9 The 
best example is provided by the discovery of adjuvants acting 
as antagonists of the CCR4 chemokine receptor, which act via 
regulatory mechanisms of the cellular adaptive immune sys-
tem. Inhibiting CCR4 receptors may give rise to adjuvantism 
as the receptor is expressed by regulatory T-cells (or Tregs) 
that normally suppress immune responses, inhibit maturation 
of DCs, and downregulate costimulatory molecule expres-
sion.10 Inhibiting CCR4 function using an effective CCR4 
antagonist, and thus blocking interaction of DC with Tregs at 
vaccination, is anticipated to exacerbate vaccine responses. By 
combining experimental validation with virtual screening, we 
have identified several potential adjuvants, acting through the 
apparent inhibition of Treg proliferation.11,12 These molecules 
behave appropriately in a variety of in vitro assays, increase the 
levels of various correlates of protection in vaccinated mice, 
and even show some enhancement in related challenge models 
observations supported by independent analysis.13 These mol-
ecules also show activity against potential cancer antigens.14
Turning to the adaptive immune system, this too can act 
as a drug target in addition to its role as the source of the fast 
growing and most robust of modern drug types: monoclonal 
antibodies. Small-molecule drugs, antibodies, and vaccines tar-
get adaptive immunity, and it can be hoped that in future other 
drug types, including cellular therapeutics such as dendritic 
cell vaccines, will also target the adaptive Immune system.
One the principal adaptive immune targets is provided 
by the trimeric MHC-peptide-TCR (pMHC-TCR) complex, 
a supramolecular complex at the heart of the cellular immune 
response.15,16 For example, the pMHC-TCR complex is a 
therapeutic target in diabetes. Coadministration of  glyphosine 
with insulin peptide B:9–23 induces IL10 production lead-
ing to prevention of diabetes in animal models.17 Likewise, 
 anti-insulin/MHC complex antibodies can block T-cell 
 activation. Similarly, specific TCR antibodies can prevent 
autoimmune diabetes in rat models.
Small molecule drugs can block allele specific peptide 
presentation to T-cells, which is both a potential mechanism 
to exploit therapeutically17,18 and a pathological mechanism 
leading to so-called adverse drug reactions.19,20 Drug-induced 
hypersensitivity reactions—such as drug rash with eosino-
philia, Stevens-Johnson syndrome, toxic epidermal necrolysis, 
and systemic symptoms—are associated with high mortal-
ity and morbidity. For many adverse drug reactions (ADRs), 
particularly cutaneous ADRs, there is a strong association 
between the reaction to certain drugs (including abacavir, 
allopurinol, carbamazepine, and other antiepileptic drugs) 
and particular HLA alleles, allowing for the prognostic pre-
diction of ADRs.
It is worth pointing out, and indeed emphasizing, in this 
context and at this stage, that developing new therapies based 
on current immunological hypothesis as supported by animal 
models, can lead to disappointing clinical results—such as the 
interaction of John Cunningham (JC) virus, a type of human 
polyomavirus exhibiting genetic similarity to SV40 and BK 
virus, which causes progressive multifocal leukoencephalopa-
thy (PML) in natural or induced immunodeficiency, with 
Natalizumab in patients with multiple sclerosis21—and even 
significant deleterious effects.22
Beyond isolated molecular targets, we can view the 
immune systems at many levels, each offering a more gener-
alised target for drug action. This can be at the level of whole 
cells, such as professional antigen presenting cells, B-cells or 
T-cells, or at the level of whole organs, from lymph nodes 
upwards. Perhaps the clearest example of this is the idea 
of using drugs to direct stems to differentiate within the 
immune environment, as has been done in other areas,23–25 
and the potential of unwanted immunogenicity of stem cell 
therapeutics.26,27
Hand-in-hand with the idea of the immune system as a 
hierarchy of targets is the concept of polypharmacy directed 
at many immune targets.28,29 Beyond combination therapies 
and the like, in recent years, a new paradigm of drug dis-
covery has begun to emerge: so-called systems pharmacology 
or polypharmacology. Systems pharmacology (or polyphar-
macology) targets activity against a pathway or, more gener-
ally, a large and complex system or subsystem of a pathway, 
rather than activity against a single, isolated receptor. In our 
case, the system would be the immune system or a discrete 
subsystem within it. All drugs have side effects or off-site 
activity; thus, drugs can be designed to target many targets, 
and such drugs combined to form complex formulations 
simultaneously affecting many targets. Thus, much recent 
interest focusses on identifying ligands with clearly defined 
polypharmacology arising from the increased awareness of 
the multiple interactions of existing drugs and the likely 
improved efficacy of treatments, which engage at several 
points in biological systems. When commencing a multi- 
target drug discovery project, it is easy enough to search 
compound databases for starting points, seeking molecules 
that hit sets of homologous or distinct targets. Like one view 
of Chinese medicines, developing complex multi-potent drug 
combinations, possibly working at a subclinical level, would 
have a general yet beneficial effect in combatting both thera-
peutically and prophylactically chronic and infectious dis-
ease, since complex, refractory, and unsatisfying conditions 
probably require equally complex and unsatisfying multiple 
interventions.
The immune system is a potent cornucopia of new drug 
targets and drug-mediated mechanisms for treating both 
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chronic and autoimmune disease, as well as infectious  disease, 
and also a fascinated and bountiful fountainhead of new chem-
ical moieties of all kinds. We have highlighted that both old 
style small-molecule drugs and new therapies, such as SMAs 
and designed peptides, can be used to address such targets, 
heralding a new era of immunological drug discovery. Yet the 
immune system is also a Pandora’s box, as it contains immense 
hope yet also brings forth the spectre of extreme immune 
reactions and ADRs, mediated by innate and adaptive immu-
nity, to new drugs, both small-molecule and macromolecular, 
whether or not they target the immune system specifically.
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